mage



## In the United States Patent & Trademark Office

In re Application of:

Hott, J.S. et al.

Examiner:

Nolan, P.J.

Serial No.:

10/005,512

Art Unit:

1644

Filed on:

November 7, 2001

Atty. Dkt.:

03514.159

For:

An Immunotoxin (mAB-RICIN) for the Treatment of

Focal Movement Disorders

Reply

Hon. Commissioner for Patents PO Box 1450 Arlington, VA 22313-1450

Dear Sir:

In Response to the Official Action of December 31, 2003, issued with respect to the above-identified patent application, Applicants respectfully request entry and consideration of the following Reply comprising Introductory Comments, Amendments to the Specification, and Remarks.

## **Introductory Comments**

This Reply has been formatted in attempted compliance with the revised provisions of 37 CFR 1.121. There are no requested Amendments to the Claims.

No fee is believed to be due in order for the timely consideration of this Reply. If, however, the Commissioner determines that such a fee is required, then the Director is authorized to charge any (Large Entity) fee required for consideration of this submission to Deposit Account 50-0548.